FDA Approves Cefepime-Zidebactam Injection - Scorecard - MDSpire
Advertisement
FDA Approves Cefepime-Zidebactam Injection
Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.
Clinical Scorecard: FDA Approves Cefepime-Zidebactam Injection
At a Glance
Category
Detail
Condition
Key Mechanisms
Combination of a fourth-generation cephalosporin and a non-beta-lactam antibacterial with a beta-lactamase inhibitor, acting synergistically on multiple penicillin-binding proteins (source: Wockhardt).
Target Population
Care Setting
Key Highlights
Cefepime and zidebactam achieved a composite clinical cure and microbiologic response rate of 89% at test-of-cure visit.
Approval based on phase 3 ENHANCE-1 trial involving 530 patients across multiple countries.
Treatment was generally well tolerated.
Guideline-Based Recommendations
Diagnosis
Diagnosis of cUTI and acute pyelonephritis based on clinical presentation and microbiological testing (source: Wockhardt).
Management
Cefepime and zidebactam indicated for treatment of cUTI caused by susceptible strains (source: Wockhardt).
Monitoring & Follow-up
Monitor for clinical response and potential adverse effects during treatment (source: Wockhardt).
Risks
Increased risk of life-threatening complications in patients with multidrug-resistant bacterial infections (source: Wockhardt).
Patient & Prescribing Data
Adults with complicated urinary tract infections caused by susceptible Gram-negative pathogens.
Cefepime and zidebactam is effective against strains of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae complex, and Pseudomonas aeruginosa.
Clinical Best Practices
Utilize cefepime and zidebactam for patients with infections caused by susceptible Gram-negative pathogens (source: Wockhardt).
Consider the history of antimicrobial resistance when prescribing (source: Wockhardt).
